Skip to Content

Join the 'Zinplava' group to help and get support from people like you.

Zinplava News

'Immunotherapy' in Monkeys Shows Promise as Long-Term HIV Treatment

Posted 13 Mar 2017 by Drugs.com

MONDAY, March 13, 2017 – Lab experiments with monkeys suggest that "immunotherapy" holds promise as a long-term treatment for HIV, researchers say. Treatment with two anti-HIV antibodies right after infection might help keep the AIDS-causing virus in check for a prolonged period, according to the new study. Despite an arsenal of HIV drugs, effective long-term treatment remains elusive because inactive versions of the virus lie in wait for an opportunity to attack the immune system, said the researchers from Rockefeller University in New York City and the U.S. National Institutes of Health. "This [new] form of therapy can induce potent immunity to HIV, allowing the host to control the infection," said Michel Nussenzweig, head of Rockefeller's laboratory of molecular immunology. "It works by taking advantage of the immune system's natural defenses, similar to what happens in some forms ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Hizentra, RhoGAM, Gamunex, Diagnosis and Investigation, Gammagard, Hepatitis B Immune Globulin, Privigen, Immune Globulin Intravenous, Gamunex-C, Sandoglobulin, Vivaglobin, Rhophylac, Synagis, Immune Globulin Subcutaneous, Nabi-HB, WinRho SDF, Rabies Immune Globulin, Human, Carimune

Health Tip: Could Allergy Shots Help You?

Posted 21 Feb 2017 by Drugs.com

-- If you have allergies, regular shots (immunotherapy) are designed to make you less sensitive to allergens over time. The American Academy of Allergy, Asthma and Immunology says you may be a candidate for allergy shots if: Your symptoms are moderate-to-severe and your allergy season lasts a few months or more. You want to avoid long-term use of allergy medications. You can commit the time needed for getting regular allergy shots. You can afford the cost of allergy shots and related medical visits. Read more

Related support groups: Allergic Reactions, Allergies, Benadryl, Hydroxyzine, Zyrtec, Promethazine, Claritin, Loratadine, Allegra, Diphenhydramine, Allergic Rhinitis, Phenergan, Hay Fever, Vistaril, Cetirizine, Cyproheptadine, Atarax, Fexofenadine, Epinephrine, Periactin

Drug May Be New Weapon Against a 'Superbug'

Posted 25 Jan 2017 by Drugs.com

WEDNESDAY, Jan. 25, 2017 – A newly approved drug may help in the battle against Clostridium difficile – a potentially fatal "superbug" gut infection that has become a scourge in U.S. hospitals. In two clinical trials, researchers found that the drug, called bezlotoxumab (Zinplava), cut the risk of a recurrent C. difficile infection by almost 40 percent. That's important, because the gut infection commonly comes back after treatment with antibiotics – around 20 percent of the time, according to the U.S. Centers for Disease Control and Prevention. The infection can also make people seriously ill, with symptoms ranging from diarrhea to life-threatening inflammation of the colon, the CDC says. Zinplava has already been approved by the U.S. Food and Drug Administration, and it should be available early this year, according to Merck, the drug's maker. That approval was based on the ... Read more

Related support groups: Infections, Diarrhea, Bacterial Infection, Clostridial Infection, Diarrhea, Acute, Infectious Diarrhea, Zinplava, Prevention of Clostridium Difficile Infection Recurrence, Bezlotoxumab

FDA Approves Merck’s Zinplava (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection

Posted 25 Oct 2016 by Drugs.com

KENILWORTH, N.J.--(BUSINESS WIRE) October 21, 2016 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Zinplava (bezlotoxumab) Injection 25 mg/mL. Merck anticipates making Zinplava available in first quarter 2017. Zinplava is indicated to reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older who are receiving antibacterial drug treatment of CDI and are at high risk for CDI recurrence. Zinplava is not indicated for the treatment of CDI. Zinplava is not an antibacterial drug. Zinplava should only be used in conjunction with antibacterial drug treatment of CDI. CDI is caused by bacteria that produce toxins, including toxin B. Symptoms of CDI include mild-to-severe diarrhea, abdominal pain and fever. The incidence of recurrent CDI is higher in certain ... Read more

Related support groups: Clostridial Infection, Zinplava, Bezlotoxumab

Ask a Question

Further Information

Related Condition Support Groups

Prevention of Clostridium Difficile Infection Recurrence

Zinplava Patient Information at Drugs.com